Detalles de la búsqueda
1.
Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.
Blood
; 132(4): 393-404, 2018 07 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-29567798
2.
Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily.
Haematologica
; 99(7): 1204-11, 2014 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-24532039
3.
Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib.
Blood
; 117(21): 5600-6, 2011 May 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-21467546
4.
Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results.
Blood
; 117(4): 1141-5, 2011 Jan 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-21098399
5.
Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia.
Eur J Clin Pharmacol
; 69(4): 813-23, 2013 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-23052406
6.
Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase.
Eur J Clin Pharmacol
; 68(5): 723-33, 2012 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-22207416
7.
Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial.
Leukemia
; 35(5): 1344-1355, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33707652
8.
Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial.
J Hematol Oncol
; 14(1): 35, 2021 02 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-33627164
9.
Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study.
J Cancer Res Clin Oncol
; 144(5): 945-954, 2018 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-29468438
10.
Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial.
Lancet Haematol
; 3(12): e581-e591, 2016 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-27890073
11.
Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study.
J Cancer Res Clin Oncol
; 141(11): 2047-60, 2015 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-26002753
12.
Nilotinib 300 mg BID as frontline treatment of CML: prospective analysis of the Xpert BCR-ABL monitor system and significance of 3-month molecular response.
Leuk Res
; 38(3): 310-5, 2014 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-24333114
13.
Effect of the tyrosine kinase inhibitor nilotinib in patients with hypereosinophilic syndrome/chronic eosinophilic leukemia: analysis of the phase 2, open-label, single-arm A2101 study.
J Cancer Res Clin Oncol
; 139(12): 1985-93, 2013 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-24057647
Resultados
1 -
13
de 13
1
Próxima >
>>